Fig. 3 | Scientific Reports

Fig. 3

From: The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement

Fig. 3

SNT-5382 in vitro and in vivo ADME characteristics. (A) Plasma protein binding, plasma and metabolic (microsomal and hepatocyte) stability across species (human, dog and rat). (B) Pharmacokinetic profile of SNT-5382 in male Wistar rats after a single oral dose (10 mg/kg). n = 2 per time-point. (C) Tissue distribution at 1 and 4 h post a single oral dose (10 mg/kg) of SNT-5382 in various rat tissues (kidney, liver, lung and heart, n = 3 per time point).

Back to article page